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Januka Budhathoki-Uprety 1,2, Janki Shah1, Joshua A. Korsen1,3, Alysandria E. Wayne1,4,
Thomas V. Galassi 1,3, Joseph R. Cohen1, Jackson D. Harvey1,3, Prakrit V. Jena 1, Lakshmi V. Ramanathan1,
Edgar A. Jaimes1,3 & Daniel A. Heller 1,3

Microalbuminuria is an important clinical marker of several cardiovascular, metabolic, and
other diseases such as diabetes, hypertension, atherosclerosis, and cancer. The accurate
detection of microalbuminuria relies on albumin quantiﬁcation in the urine, usually via an
immunoturbidity assay; however, like many antibody-based assessments, this method may
not be robust enough to function in global health applications, point-of-care assays, or
wearable devices. Here, we develop an antibody-free approach using synthetic molecular
recognition by constructing a polymer to mimic fatty acid binding to the albumin, informed by
the albumin crystal structure. A single-walled carbon nanotube, encapsulated by the polymer,
as the transduction element produces a hypsochromic (blue) shift in photoluminescence
upon the binding of albumin in clinical urine samples. This complex, incorporated into an
acrylic material, results in a nanosensor paint that enables the detection of microalbuminuria
in patient samples and comprises a rapid point-of-care sensor robust enough to be deployed
in resource-limited settings.
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lbumin is the most abundant protein in the human body,
constituting up to 60% of plasma and plays an essential
role as a transporter of fatty acids1, biomolecules such as
hormones2, and drugs3. Albumin is ﬁltered in the kidneys and is
only present in the urine at low concentrations in healthy individuals. A concentration in the urine above an established clinical
threshold of ~30 mg/L represents a pathologic state. Diabetes4,
cardiovascular diseases5, cancers6 and some therapeutic drugs7
trigger kidney injuries that may initiate long-term adverse
effects8, leading to albuminuria—albumin protein leakage into
the urine. Thus, albumin in the urine serves as a readily accessible, noninvasive biomarker of these diseases. Microalbuminuria
describes lower concentrations, 30–300 mg/L of albumin in the
urine9; persistent microalbuminuria may progress into macroalbuminuria (>300 mg/L urinary albumin), an indicator of severe
kidney damage. Because conditions leading to microalbuminuria
may often be controlled at early stages, the early detection and
monitoring of microalbuminuria could greatly improve patient
outcomes.
Currently, a high level of albumin in urine is most commonly
detected by dipstick urinalysis10, but sensitivity is poor for
microalbuminuria11. Other techniques (Supplementary Table 1)
including chemical approaches using small molecule ﬂuorescence,
have been explored12–14; however, most are not robust enough
for clinical laboratory assessments. The current clinical method
for microalbuminuria detection is an immune-turbidimetry assay
using polyclonal antibodies against human albumin9. Antibodies
are highly sensitive, but they are expensive to produce, require
refrigeration and careful handling, and are prone to degradation.
Polyclonal antibodies are also subject to inherent batch-to-batch
variations15,16. As such, they are poorly suited to limited-resource
settings with underdeveloped infrastructure and point-of-care
diagnosis. Thus, new methods are desirable to detect microalbuminuria in point-of-care and/or low-resource settings.
Synthetic molecular recognition denotes the development of
molecular recognition elements that circumvent the need for
natural recognition molecules such as antibodies. Nanoparticles
can consist as templates for artiﬁcial molecular recognition17–19
serving as synthetic antibodies/immunosensors20. Many nanoparticles appear to bind to serum abundant proteins such as
albumin non-speciﬁcally21. Fe–Pt nanoparticles22, quantum
dots23, gold and silver nanoparticles24, and carbon nanotubes25
are some representative materials that bind to albumin. The
binding ability of albumin to a wide range of materials provides
both an opportunity for as well a challenge towards the development of an albumin-speciﬁc sensor.
Single-walled carbon nanotubes (SWCNTs) exhibit unique
photophysical properties that enable the development of quantitative optical biosensors. These carbon nanotubes exhibit stable
photoluminescence in the near-infrared region26, a suitable
spectral window to measure responses in complex bioﬂuid samples27 without interference from common metabolites ﬂuorescent
in the UV-visible range28. Carbon nanotube emission is sensitive
to local dielectric, hydrophobicity, redox potential, and surface
potential, enabling optical sensing29. Nanotube optical sensors
have been employed to detect analytes such as oligonucleotides30,
cancer antigens31, proteins32, neurotransmitters33, reactive oxygen species34, lipids35,36, and to measure strain37 in solid structures. We previously reported that photophysical properties and
surface chemistry on SWCNTs can be modulated via encapsulation in helical polycarbodiimides38, polymers that enable
unique control over nanotube surface chemistry, interactions with
biomolecules and cells39, and facilitate subcellular targeting40.
Wearable and ﬂexible sensors for biological and medical
applications have recently garnered signiﬁcant interest, and
wearable sensors for the detection of heart rate and ECG have
2

already reached the consumer electronics market41. Flexible
electronics for the recording of cellular electronic activities42 and
measurements of neurological activity have been under intense
laboratory development for biological research applications, as
well as eventual medical uses43,44. Sensor paints are under
development for applications such as wound care45. Such materials could ﬁnd applications in ﬂexible and wearable sensors,
which may transmit medical information to care providers in
under-resourced settings46.
Herein, we investigated synthetic molecular recognition to
modulate carbon nanotube photoluminescence response to
albumin, which we then developed into a robust, rapid assay, in
addition to a nanosensor paint for the detection of microalbuminuria. We designed and synthesized a suite of polycarbodiimide polymers to concomitantly encapsulate carbon
nanotubes and interact with speciﬁc features of albumin based on
the crystal structure. We found that nanotube-polymer complexes
with a carboxylate-rich, hydrophobic polymer exhibited speciﬁc
photoluminescence responses to albumin in the microalbuminuria range via both intensity enhancement and a hypsochromic shift (blue shift), potentially due to mimicry of the
head group of albumin-binding fatty acids. The sensitivity of the
response (up to 3 mg/L) is comparable to an immunoturbidimetry assay (1 mg/L)47, the most widely-used existing clinical
method. The potential interferent proteins such as transferrin, γglobulins, and degraded albumin elicited either negligible change
or bathochromic instead of hypsochromic shifting of the nanotube emission, imparting selectivity in the testing conditions. We
hypothesize that such selectivity is due to the carboxylatefunctionalized polycarbodiimide acting as a molecular mimic of
the head group of albumin-binding fatty acids, via both hydrophobic and Coulombic interactions, to provide synthetic molecular recognition of albumin. We found that the sensor
functioned in clinical urine samples from human patients with
microalbuminuria. To see if this sensor could be incorporated
into a versatile form factor, we tested the functionality of the
polymer-nanotube complexes in a scaffold that could be applied
and dried onto surfaces as paint, and found that an acrylic
mixture enabled retention of sensing ability. The resulting
material is a free-standing optical sensor paint capable of measuring microalbuminuria in patient samples.
Results
Sensor development. We synthesized polycarbodiimide-SWCNT
(PCD-SWCNT) complexes to screen for speciﬁc and selective
interactions with albumin. We synthesized polycarbodiimides
polymers incorporating both phenyl rings to elicit non-covalent
π–π interactions to the graphitic sidewall of the nanotube38 and
diverse functional groups (Fig. 1a, Supplementary Fig. 1) to
interact with analytes. Among them, we synthesized a hydrophobic carboxylated chain to mimic fatty acids, which are known
to bind to albumin48. We also synthesized polymers with amine
and polyethylene glycol (PEG) groups that could interact via
Coulombic and hydrophobic interactions, respectively. The
polymers and polymer-nanotube complexes (Fig. 1b) were synthesized and characterized as reported previously38–40. The
optical properties of the polymer-nanotube complexes were
conﬁrmed by UV-VIS-NIR absorbance and NIR photoluminescence measurements as reported38,39. The various PCDSWCNTs were exposed to 6.25–100 mg/L albumin, and their
near-infrared photoluminescence spectra (900–1400 nm) were
measured under 730 nm laser excitation. We focused on the
response to the (9, 4) nanotube chirality due to its optical resonance at 730 nm and emission near 1120 nm, where there is
minimal absorbance due to water or tissues, resulting in a high

NATURE COMMUNICATIONS | (2019)10:3605 | https://doi.org/10.1038/s41467-019-11583-1 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11583-1

b

a
N

N

N
N N

O
3

1
0
–1

25

0

6.

1050

Wavelength shift (-0) nm

1.8
+ Albumin
– Albumin

1.4
1.2
1.0
10

1150

1200

1250

1300

1350

Wavelength (nm)

g
2.0

5

1100

15

20

h

–Albumin

+Albumin
6

0.5
0.0
– Albumin

–0.5

4

+ Albumin
–1.0
–1.5

2

Height (nm)

Intensity fold change (I /I0)

1 × 106

Albumin (mg/L)

f

0

50
25
6.25
0

1.5 × 106

5 × 105

Albumin (mg/L)

1.6

Albumin (mg/L)
100

–2

10

50

25

12

6.

.5

1.0

Intensity (a.u.)

1.2

2

Polymer-cloaked
nanotube

2 × 106

0

1.4

e

PEG-PCD-SWCNT
Amine-PCD-SWCNT
Carboxy-PCD-SWCNT

50

Carboxy-PCD-SWCNT

d

Nanotube

10

1.6

Polymer

PEG-PCD

25

PEG-PCD-SWCNT
Amine-PCD-SWCNT

25

Intensity fold change (I /I0)

Amine-PCD

1.8

N N

20
O

.5

Carboxy-PCD

c

O

H2N

Albumin

N

12

O

N n

N
N N

Wavelength shift (-0) nm

HO

N
N n

N n

–2.0
0

5

Time (min)

10

15

20

0

Time (min)

Fig. 1 Optical nanosensor for albumin detection. a Schematic showing PCD structures. b PCD-SWCNT complex formation and its interaction with albumin
protein. c Emission intensity response of the PCD-SWCNT complexes ((9, 4) chirality) to albumin. d Emission wavelength response of the PCD-SWCNT
complexes to albumin ((9, 4) chirality). e Photoluminescence emission spectra of carboxy-PCD-SWCNT complexes upon addition of albumin
(concentration increasing from bottom to top). f Response curve of emission intensity of carboxy-PCD-SWCNT complexes ((9, 4) chirality) to albumin.
g Response curve of emission intensity of carboxy-PCD-SWCNT complexes to albumin ((9, 4) chirality). h Atomic fore microscopy height proﬁle images of
carboxy-PCD-SWCNT complexes and the same complexes upon exposing to albumin. Scale bar indicates 50 nm. Error bars represent standard deviation
for n = 3 technical replicates

signal intensity from a relatively low concentration of nanotubes36. The response to albumin was a monotonic, dosedependent emission intensity enhancement and wavelength shift
towards shorter wavelengths (blue shift/hypsochromic shift) only
for the carboxy-PCD-SWCNT sample (Fig. 1c–d). We observed a
consistent blue-shift response from all observed photoluminescent nanotube species (Fig. 1e, Supplementary Figs. 2
and 3). The PEG-PCD-SWCNTs showed a negligible response to
albumin, while the amine-PCD-SWCNTs responded via slight
quenching of emission intensity and a small degree of emission
red-shifting/bathochromic shifting (Fig. 1c, d). We attribute this
response from amine-PCD-SWCNTs to accumulation of electrostatic charge on the nanotube surface and, potentially,
agglomeration. The electrostatic attraction between the positively
charged amine-PCD-SWCNTs and negatively charged albumin
likely induced a bathochromic shift in the nanotube emission49.
The electrostatic attraction between macromolecules may also
prompt nanotube-nanotube agglomeration, which is known to
cause photoluminescence quenching and red-shifting of nanotube
emission via exciton dispersion50.
Upon identifying carboxy-PCD-SWCNTs as a potential sensor
(henceforth referred to as the nanosensor) for albumin, we
assessed the response kinetics. The results from the measurements showed that both the emission intensity (Fig. 1f) and blue
shift (Fig. 1g) approached a maximum by 20 min with apparently

pseudo ﬁrst-order kinetics. The rate of intensity change was
similar to that of the wavelength change with rate constants of
0.2140 min−1 and 0.1845 min−1, respectively.
We investigated the topology of the albumin-exposed nanosensor using atomic force microscopy (AFM). Height measurements on carboxy-PCD-SWCNT complexes/nanosensors showed
that our preparation yielded singly-dispersed nanotubes with an
average diameter of ~1–2 nm and median length of ~178 nm
similar to previous ﬁndings39. The nanosensors were then
incubated with albumin for 30 min at room temperature, excess
albumin was removed via ﬁltration, and the sample was deposited
onto freshly cleaved mica, rinsed and dried before imaging via
AFM under dry conditions. The images showed a resulting height
increase of the nanosensors up to 4 nm (Fig. 1h, right panel,
Supplementary Fig. 7), which closely resembles the size of
albumin24,51, suggesting a monolayer deposition of albumin on
the nanotube surface.
Sensor response with other proteins. We investigated whether
the nanosensor could discriminate albumin from other proteins
that could also be present in urine. Potentially interfering proteins
were selected, including transferrin, which can leak into urine
under abnormal kidney conditions52, and γ-globulin, indicative
of glomerular damage53. We interrogated the nanosensors with
transferrin and γ-globulin, resulting in signiﬁcant, but attenuated
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Fig. 2 Sensor response to interferents, and sensor mechanism. a Emission intensity response of the nanosensor to various proteins. b Emission wavelength
response of the nanosensor to protein interferents. c SDS-PAGE gel where: lane 2 contains albumin at pH 7 incubated at room temperature for 30 min; lane
3 contains albumin incubated at pH 2 in PBS at room temperature for 30 min followed by neutralization; lane 4 contains albumin incubated in urine at pH 2
for 30 min followed by neutralization. d Emission intensity response of the nanosensor to intact albumin (bars 1–2, corresponding to lanes 2–3, respectively,
in panel c) and degraded albumin (bar 3, corresponding to lane 4 in panel c). e Emission wavelength response of the nanosensor to intact albumin (bars
1–2, corresponding to lanes 2–3 in panel c) and degraded albumin (bar 3, corresponding to lane 4 in panel C). f A proposed model of albumin interaction
with the carboxy-PCD-SWCNT nanosensor. Data in panels a, b and d, e present the (9, 4) nanotube chirality. Error bars represent standard deviation for
n = 3 technical replicates

intensity enhancement, as compared to albumin (Fig. 2a).
Importantly, there was only a small change in emission wavelength (<0.5 nm), that became evident at higher doses (≥50 mg/L)
of γ-globulin (Fig. 2b). Albumin derived from bovine, mouse, and
human plasma all elicited consistent responses from the nanosensor (Supplementary Fig. 4A, B).
We hypothesized that if the binding pockets of albumin are
disrupted by protein degradation, the sensor response could
deviate from that observed with intact albumin and limit
selectivity. Following a literature protocol54, we degraded albumin
in urine under transient pH changes to low pH (incubated for 30
min in urine at low pH), as conﬁrmed by SDS-PAGE analysis,
Fig. 2c, and compared the sensor response in native and degraded
albumin. In the case of degraded albumin, the sensor did not
recapitulate the response. Degraded albumin attenuated the
nanotube intensity (Fig. 2d), and elicited a bathochromic
response, instead of a hypsochromic response (Fig. 2e). This is
potentially consistent with loss of ligand binding capacity of
proteins on degradation, wherein non-speciﬁc interactions of the
degraded albumin may have caused the bathochromic response
due to electrostatic interactions of the protein with the nanotube
sidewall40,49.
We propose the following model for sensor interaction with
albumin that results in blue-shifted emission (Fig. 2f) based on
our experimental observations and known mechanisms of fatty
acid binding to albumin55. Albumin presents high-afﬁnity
binding sites for fatty acids56. The crystal structure of fatty
acid-bound albumin shows the presence of one or more basic
amino acids (lysine/arginine/histidine) in hydrophobic pockets,
which form salt bridges with the carboxylic acid on the fatty
acid57 and aromatic amino acids55, which also exhibit afﬁnity for
4

the fatty acid58,59. We surmised that the structural similarities of
the carboxylic acid-functionalized polycarbodiimide and the fatty
acid, including the carboxylic acid and hydrophobic linker, on the
polymer, could substitute for the fatty acid to promote the speciﬁc
interactions, including salt bridge, hydrogen bonding, and
hydrophobic interactions, between the fatty acid carboxylic head
group58,59 and albumin. The presence of aromatic groups along
the nanotube surface likely prompt π–π interactions with
aromatic amino acid residues located in the binding pockets,
further stabilizing the binding of albumin and displacing water
from the nanotube surface.
The nanotube emission response behavior, upon interaction
with albumin, is somewhat complex. The hypsochromic emission
response is caused by the known solvatochromic behavior of
nanotube emission60, caused here by displacement of water from
the surface and interaction with hydrophobic residues on the
protein. The intensity increase is likely similarly caused by the
displacement of water from the nanotube surface, but is
potentially affected most by the change in the redox environment
upon removal of water61. The intensity change is thus faster than
the hypsochromic response, and potentially exhibits twocomponent kinetics, as the curve does not ﬁt precisely to a
pseudo ﬁrst-order model. The ﬁrst component is likely due to
adsorption resulting in rapid surface water displacement,
followed by a slower conformational change of the protein on
the sensor, which results in an increased hydrophobic environment on the nanotube surface. The intensity, more sensitive to
the redox environment, changes most quickly, while the
wavelength change is more strictly solvatochromic, responding
most strongly to the hydrophobic interaction with the protein.
The hydrophobic pockets are generally less accessible in soluble
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proteins and may interact with the nanotube only after
conformation changes. In the case of sensor interaction with
degraded albumin or other proteins, transferrin and γ-globulin,
the response is mediated by mild water displacement, leading to
an intensity increase, and a small degree of electrostatic
interactions between the proteins and the nanotube surface,
leading to a small bathochromic response49.
We next tested our sensor in human whole urine samples.
Urine from a healthy donor was collected and the quality of the
urine assessed using a commercial dipstick urinalysis strip
(Siemens Healthcare Diagnostics Inc.) to ensure absence of
measurable proteins. Various concentrations of albumin, corresponding to microalbuminuria, were spiked into the urine. The
sensor exhibited a response to the spiked albumin via enhanced
emission intensity and a blue-shifted emission wavelength (Fig. 3a,
b). In the whole urine sample, the blue shift exhibited a
monotonic increase with albumin dose, while several high
concentrations exhibited a maximum followed by a partially
reversed response. This phenomenon was more prominent in the
response of certain nanotube chiralities (Supplementary Fig. 3)
and some conditions more than others, such as human urine
(Fig. 3b), most likely due to molecular crowding. Such high

concentration effects are common in macromolecular assays such
as single-step immunological assays, including immunoturbidimetric assays62 and are generally corrected by dilution63.
We tested the nanosensor in human urine samples collected
from patients with microalbuminuria. Waste human urine
specimens collected with IRB approval were used at MSKCC.
The nanosensor responded via intensity enhancement (Fig. 3c),
similar to that previously observed in the albumin-spiked urine
and in albumin in buffer conditions. However, notably, the
emission wavelength exhibited a bathochromic response/red shift
in the microalbuminuria samples (Fig. 3d). We investigated
further via SDS-PAGE analysis of the urine samples, which
showed a signiﬁcant presence of several different proteins,
including albumin plus other lower molecular weight proteins
(Fig. 3e, panel 3–6). We then measured total protein in these
samples via a standard clinical turbidimetry method64. The total
protein measurement correlated with the nanosensor red-shifting
response (Fig. 3d). On further analysis, we found that the ratio of
albumin/total protein (Supplementary Table 2) strongly correlated with the degree of emission red-shifting (Fig. 3f). Small
molecular weight proteins present in the microalbuminuria
samples likely behaved in a similar manner as degraded albumin,
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investigated above, resulting in red-shifting behavior. Since the
sensor responded to these samples with a net red shift, we
conclude that the red shift from other interfering proteins
competed with the blue-shifting response from albumin.
We investigated the de-convolution of the sensor response to
albumin from the response to other proteins in the patient
samples. We attempted to remove small molecular weight
proteins via ﬁltration through a 50 kD molecular weight cutoff
membrane. On subsequent interrogation of the sensor with the
ﬁltered patient samples, the intensity was enhanced (Fig. 3g). The
emission wavelength exhibited a distinct blue shift, however
(Fig. 3h), similar to the response to albumin in buffer and spiked
samples. We conclude that the removal of small molecular weight
proteins from patient samples via ﬁltration recapitulated the
hypsochromic response of the sensor due to the removal of
proteins that prompted electrostatic-induced bathochromic
shifting behavior of the nanotubes.
Paint-immobilized nanosensor. We investigated the incorporation of the nanosensor into a form-factor that can be applied to
surfaces. We blended the aqueous suspension of our nanosensor
with a commercial varnish and casted it into a dry ﬁlm (Fig. 4a).
Albumin was applied on the surface of the ﬁlm and the response
was monitored using a custom-built ﬁber optic probe system
(Fig. 4b, c) using a 730 nm continuous wave laser source and
spectrometer/NIR array detector, previously described31,61. The
paint-immobilized nanosensors exhibited emission enhancement
(Fig. 4d) and a blue shift (Fig. 4e) in response to albumin (Supplementary Fig. 5). We then tested the nanosensor-embedded
paint against urine samples from patients with microalbuminuria
(Supplementary Table 3), after ﬁltration using the 50 kD MWCO

a

ﬁlters, described above. The sensors responded to these samples
via a hypsochromic shift, largely as expected (Fig. 4f, Supplementary Fig. 6). The sensor-embedded paint exhibited some
variations in center wavelength values, of ±1.12nm, and intensity
differences of up to 2× (Supplementary Fig. 6). Therefore, the
reference emission was collected individually for each measurement, corresponding to a location within the paint material.
However, the relative changes in sensor response to albumin
remained unaffected by the location. Interestingly, the paintimmobilized sensor exhibited higher magnitudes of intensity
changes and wavelength shifts upon exposure to albumin.
Although the exact mechanism for this observation remains to be
elucidated, the improved signal might have resulted from combination of a number of factors such as a decrease in hydrophilic
(water) content around nanotubes, and/or the acrylate paint,
which contains carboxy moieties, may have facilitated favorable
molecular interactions that improved protein binding to the
paint/sensor material.
In conclusion, we investigated a synthetic molecular recognition optical nanosensor for the quantitative measurement of
albumin in patients with microalbuminuria. The nanosensor was
comprised of photoluminescent single-walled carbon nanotubes
cloaked with a carboxylate-functionalized polycarbodiimide
polymer–materials that afford the relative ease of production,
storage, handling, stability, and robustness as compared to
antibodies used in current methods. The rapid sensor response
under ambient conditions in minimally processed urine samples
suggests that this antibody-free detection may facilitate diagnosis
in point-of-care and resource-limited settings.
The work investigated synthetic molecular recognition via
polymer synthesis informed by protein structure. We surmise that
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binding and speciﬁcity of the polymer structure that conferred a
unique optical response of the nanotube to albumin is mediated
by electrostatic and hydrophobic interactions between the
carboxylic acid functional groups on the polymer surface with
basic amino acid groups in the binding pocket, in addition to
hydrophobic/aromatic amino acid afﬁnity to the hydrophobic
polymer/nanotube structure.
The hypsochromic emission response of the sensor to albumin
was caused by the known solvatochromic behavior of nanotube
emission via displacement of water from the surface and
interaction with hydrophobic residues on the protein. The
intensity, more sensitive to the redox environment, likely changed
quickly because of the rapid displacement of water upon binding
of the albumin to the sensor, while the wavelength change was
more strictly solvatochromic, responding most strongly to the
hydrophobic interaction with the protein hydrophobic pockets,
which are generally less accessible and may interact with the
nanotube only after conformation changes. We found that the
antibody-free detection of albumin exhibited a similar sensitivity
compared to clinical immunoturbidimetry assays.
We also found that the nanosensor, integrated into a portable,
free-standing paint, allows protein detection in patient urine
samples. This “nanosensor paint” potentially opens new opportunities for engineering of point-of-care and wearable devices for
clinical and ﬁeld uses. The ﬁnding warrants further developmental steps towards these applications.
Methods
Materials. Reagents and solvents were purchased from Sigma–Aldrich, Milwaukee,
WI, Acros Organics, and Fisher Scientiﬁc, Fair Lawn, NJ, and used as received.
Anhydrous toluene and anhydrous and inhibitor-free diethyl ether were used in
catalyst synthesis and puriﬁcation. Anhydrous and inhibitor-free tetrahydrofuran
was used for ‘click chemistry’. Bovine Serum albumin, mouse serum albumin, and
human serum albumin were purchased from Sigma–Aldrich.
Preparation of polymer-nanotube complexes. To prepare aqueous suspensions
of polycarbodiimide single-walled carbon nanotube complexes, HiPco SWCNTs
(Unidym, Lot # R1901, 1.5 mg) were added to an aqueous suspension of polycarbodiimide polymer functionalized with either primary amine side chains
(amine-PCD, 5 mg/mL, pH ~3, total volume 1 mL) or functionalized with carboxylic acid side chains (carboxy-PCD, 5 mg/mL, pH ~ 9, total volume 1 mL). The
polymer synthesis and characterization has been described in Supplementary
Note 1. The heterogenous mixtures were sonicated at low temperature by using a
probe-tip sonicator for 20 min (750 W, 20 kHz, 40% Amplitude, SONICS VibraCell). The solution was kept at low temperature using a CoolRack M30 PF (BioCision), precooled at −20 °C. The resulted dark solution was centrifuged twice for
1 h at 30,000 rcf at 20 °C (Centrifuge 5430 R, Eppendorf). About ¾ of the supernatant was collected and pellets were discarded to remove unsuspended material.
The supernatants were ﬁltered through centrifugal ﬁlter units (100 kDa MWCO,
Amicon Ultracel, Merck Millipore Ltd.), washed with water four times to remove
small molecules and excess polymer. A litmus paper test was performed to conﬁrm
the removal of acid/base from the suspension. All the aqueous suspensions were
prepared using ultrapure water (18.2 mΩ). The resulting dark black suspensions of
polymer-nanotube complexes were stored at room temperature under ambient
conditions.
Characterization of polymer-nanotube complexes in solution. The suspensions
were characterized by visible-near-infrared (VIS–NIR) absorbance and NIR
ﬂuorescence spectroscopies. The VIS–NIR absorption spectra were measured with
a JASCO V-670 spectrophotometer (Tokyo, Japan). The concentration of nanotubes was calculated using the extinction coefﬁcient Abs625 = 0.036 L mg−1 cm−1.
Near-infrared photoluminescence excitation/emission (PL) measurements were
performed on a home-built instrument consisting of an IsoPlane SCT 320 spectrograph and PIoNIR InGaAs detector (Princeton Instruments) connected to an
Olympus IX71 inverted microscope as reported38. The excitation was via using a
SuperK EXTREME supercontinuum white light laser source connected to a Varia
variable bandpass ﬁlter accessory capable of tuning the output from 490–825 nm
with a bandwidth of 20 nm (NKT Photonics). The excitation beam was ﬁltered
with a long pass dichroic mirror with a cut on wavelength of 900 nm. The excitation light was shaped and fed into the back of the microscope and passed through
a 20X nIR objective (Olympus) to illuminate 100 μL aqueous nanotube sample at a
concentration of 2–5 mg/L in 96-well plates. The emission was collected through
the ×20 near-infrared objective (Olympus), passed through a dichroic mirror and

ARTICLE

recorded from 915 to 1354 nm with a resolution of ~0.7 nm. The light was collected
by a NIRvana InGaAs 640 × 512 pixel array detector (Princeton Instruments). A
HL-3-CAL-EXT halogen calibration light source (Ocean Optics) was used to
correct for wavelength-dependent artifacts, according to the manufacturer’s speciﬁcation. A Hg/Ne pencil style calibration lamp (Newport) was used to calibrate
the spectrometer wavelength. Ensemble spectroscopy measurements were performed using the aforementioned spectrometer upon excitation at 730 nm using
the supercontinuum laser source.
In brief, data were collected using a custom Labview (National Instruments)
automation program. The NIR spectra were corrected for: (i) wavelengthdependent detector efﬁciency, using an Ocean Optics reference light source,
according to the manufacturer’s speciﬁcation, and (ii) pixel to wavelength
calibration, using a HgNe pen lamp and an internal calibration routine provided by
Princeton Instruments. The calibrated data were ﬁrst processed by subtracting the
blank signal obtained from a well containing buffer only. In the backgroundsubtracted data, an automated ﬁtting routine (written in Matlab (R2014a, The
MathWorks), code available upon request) was used to identify emission peaks,
and to ﬁt each emission spectrum with a Lorentzian function. The center
wavelength, peak height and linewidth were obtained from the ﬁtted spectra.
Graphs were plotted using GraphPadPrism (7.01) software. The reference center
wavelength in solution was within ±0.23 nm between measurements. Reference
data were collected separately for each experiment.
Note: For photoluminescence excitation/emission (PLE) maps, areas of much
low intensity for emission at 1060 nm and excitation around 575, 740, and 800 nm,
were sometimes noted, unlike in PLE maps of similar carbon nanotubes,
(Supplementary Fig. 2) due to over-subtracting the blank from the data. In our
instrument, which incorporates a ﬂuorescence microscope, the excitation results in
emission from trace neodymium present in the optical elements within the
microscope objective itself (Olympus LCPlan N 20 × 0.45 IR) at ~1060 nm, due to
excitation peaks (at ~575, 740 and 800 nm). In some SWCNT solutions, removal of
this strong background emission can result in over-subtraction, resulting in the
zero (dark blue) regions (Supplementary Fig. 2).
Zeta potential (surface charge) measurements were conducted by suspending
polymer-nanotube complexes (~1–2 mg/L) in ultrapure water (18.2 mΩ) in a 1 mL
folded capillary cell (Malvern). Measurements were conducted at room
temperature using a Zetasizer Nano-ZS instrument (Malvern).
For atomic force microscopy, carboxy-PCD-SWCNTs were treated with
albumin (50 mg/L) and incubated at room temperature for 30 min; excess albumin
was removed via centrifugal ﬁltration (100 kD MWCO ﬁlter, Amicon; 10,000 rcf, 6
min) and reconstituted in water. The polymer-nanotube complexes (1 mg/L) were
deposited onto a freshly cleaved mica surface (Pelco Mica Disc, V1, Ted Pella) and
allowed to stand for 1 min before washing the surface with deionized water two
times to remove unbound carbon nanotubes. The mica surface was dried at room
temperature with ultrapure nitrogen prior to imaging. AFM images were collected
using Asylum MFD-3D-BIO in AC mode using AC240TS tips (Asylum Research).
The typical scan size was 2 µm and scan rate was 0.25 Hz–0.5 Hz. The images were
processed with Igor software.

Sensor response to albumin in solution. Human serum albumin (≥99% pure,
essentially globulin free lyophilized powder, Sigma–Aldrich) solution was prepared
by dissolving albumin in sterile PBS (1×) at room temperature. The sample solution was either used immediately or stored at 4 °C and used within a week. An
aqueous suspension of polymer-SWCNTs complexes (90 µL per well) was deposited into a 96-well plate. Albumin (speciﬁed concentration, 10 µL per well) was
added to the well and the solution was thoroughly mixed using a pipette. The
solution was then allowed to equilibrate at room temperature for 1 h, except in the
kinetic measurements experiments, prior to optical measurements. The samples
were excited at 730 nm. All the measurements were performed in triplicate and
repeated at least three times. The data presented are from three technical replicates
for the experiments. The results were found to be reproducible within 5–10% error.
Kinetic measurements of the nanotube response to albumin in solution was
performed following a similar protocol as described above. All the measurements
were performed under ambient conditions. Brieﬂy, the polymer-nanotube
complexes in solution (90 µL, 2 mg/L) were added to a 96-well plate and excited at
730 nm; the emission was continuously measured. After 10 min, albumin solution
(10 µL) was quickly added to obtain a ﬁnal concentration of albumin of 100 mg/L,
mixed thoroughly by using a pipette. Emission was collected over 60 min with a 1 s
duration of acquisition per spectrum.

Paint-immobilized nanosensor preparation. Carbon nanotube paint composites
were prepared by blending together an aqueous suspension of Carboxy-PCDSWCNT complexes (200 μL, 7 mg/L concentration) and artist acrylic gel medium
(~2 g Matte Super Heavy Acrylic Gel form Liquitex®). The paint mixture was
applied onto a glass surface to make a thin ﬁlm and allowed to dry at room
temperature overnight (~10 h). The painted surface was ringed with DI water twice
to remove unbound nanotubes followed by further drying under ambient conditions for 6 h. A blank paint ﬁlm without nanotubes was prepared and used for
background spectroscopic measurements.
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Fluorescence spectroscopy on paint-immobilized nanosensor. Paintimmobilized polymer-nanotube complexes were measured using a custom-built
reﬂectance probe-based near-infrared spectroscopy system described below. The
paint, bound to a glass surface, was measured upon 730 nm excitation through the
ﬁber optic probe. Near-infrared emission was collected from the same ﬁber bundle
and collected via spectrometer-coupled InGaAs array detector. 50 μL of albumin
solution (Microalbumin calibrators, Abbott Laboratories, USA) of speciﬁed concentration was deposited on the paint surface, and emission was collected again after
1 h incubation at room temperature. The ﬂuorescence collected in the same area of
the paint prior to albumin treatment was used as the control. To measure responses
from clinical microalbuminuria samples using nanosensor paint, the urine samples
were ﬁrst processed minimally. Urine samples were ﬁltered using 50kD MWCO ﬁlters
and the ﬂow through was discarded. The residue was reconstituted with the same
volume of DI water. The sample (50 μL) was applied to the paint surface and nIR
ﬂuorescence was measured. For control experiment, healthy urine sample was used.
The optical measurement system consisted of a continuous wave 1 watt 730 nm
diode laser (Frankfurt) connected to a bifurcated ﬁber optic reﬂection probe bundle
(Thorlabs) and Czerny-Turner spectrograph with 303 mm focal length (Shamrock
303i, Andor). The sample leg of the bundle included one 200 µm, 0.22 NA ﬁber
optic cable for sample excitation located in the center of six 200 µm, 0.22 NA ﬁber
optic cables for collection of the emitted light. Long pass ﬁlters were used to ﬁlter
emission <1050 nm. The emission light was focused through a 410 μm slit into the
spectrograph. The light was dispersed using a 85 g/mm grating with 1350 nm blaze
wavelength and collected with an iDus InGaAs camera (Andor). Spectra were ﬁt to
Voigt functions using custom Matlab code.
Nanosensor response in microalbuminuria urine samples. Waste human urine
specimens collected with IRB approval were used at MSKCC. The samples were
stored at 4 °C for 4–6 days when needed. The urine samples were centrifuged (1000
rcf, 5 min) and the supernatant was collected. The supernatant was used directly or
ﬁltered through 50 kD MWCO ﬁlters twice, the ﬂow through was discarded and
the residue was reconstituted in DI water. Nanosensor solution (10 μL) was added
to urine sample (90 μL), thoroughly mixed, incubated at room temperature for
speciﬁed time (1–4 h) and the nIR ﬂuorescence was measured. The ﬁnal concentration of nanotubes in aqueous suspension was 2–5 mg/L.
Albumin degradation, to simulate conditions in urine, was performed by
following a literature protocol (Kania et al. Urinary proteases degrade albumin:
implications for measurement of albuminuria in stored samples. Ann Clin
Biochem 47, 151–157, 2010). Brieﬂy, urine sample was spiked with albumin and
pH was adjusted by adding dilute hydrochloric acid until the desired pH was
reached. The mixture was then incubated at room temperature for 30 min, followed
by neutralization by addition of sodium bicarbonate. Degradation was conﬁrmed
by SDS-PAGE gel. The lower pH caused slight quenching but no signiﬁcant effect
on emission wavelength (Fig. 2d, e).
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